Futures were showing a weak start for Wall Street last night but had improved before the opening bell this morning after Japan’s Gross Domestic Product (GDP) numbers came in worse-than-expected. The country’s GDP for the second quarter was 1.4% which was half the growth of the 2.7% figure economists had predicted. Even worse, this is way down from the 5.5% growth posted from the first quarter.
Europe was relatively quiet over the weekend and Italy is trying to raise 8 billion euros (nearly $10 billion) today after selling 12-month Treasury bills. The auction went well as demand was strong but Italy’s borrowing costs are edging up again.
The indexes opened lower but the Nasdaq was able to sniff positive territory before heading south to join the Dow and S&P. The bears had ruled Monday’s for 2+ months up until last week and looked determined to hold resistance, at least for today.
Some of our current trades are getting nice pops, including a couple from our Weekly Wrap. We offered a 6-month deal on the publication over the weekend and demand was strong. Thank You.
The publication has profiled some incredible stocks over the years, including a few 10-baggers. We were probably the only newsletter who recommended Dendreon (DNDN, $4.49, down $0.14) back in 2009 at $4 after saying the FDA would approve their prostate cancer drug, Provenge. Shares zoomed to over $50 in 2010 and when they fell below $40 last year, we said to get out.
We also profiled Imax (IMAX, $20.44, down $0.64) when shares were at $3 and before 3D became big. We said the flick Avatar would change the movie industry back in 2008 and a few years later, shares of Imax were pushing $20 after the movie made its debut in 2009. By 2011, Imax had pushed $30 and we said to get out as we saw the momentum fading.
We have profiled Vivus (VVUS, $21.74, up $0.14) and Arena Pharmaceuticals (ARNA, $7.21, down $0.06) when shares were under $5 and $2, respectively, and we said both companies had a good shot at getting their obesity drugs approved. We also have been saying Vivus has the stronger pipeline and shares could still double from current levels.
We now have another stock we are recommending for our Weekly Wrap that currently trades for under $4. Shares have traded as high as $7 over the past 52-weeks and we started coverage of the stock back in February.
Shares fell to a low of $2.20 in July but now some investors are starting to find out about their story. The stock closed at $3.10 on Friday on 10 times normal volume and insiders have been buying the stock by the boatloads.
This small-cap stock has a market cap of just $28 million but they are growing their business and you will be hearing their name in the next year or two as the company rolls out its expansion plans.
At current levels, if it reaches its prior 52-week high, it would be a 100% return. If shares move to $10+ over the next 12-24 months, you could make 200% or 300% if all goes well. The stock is up another 18% to $3.65, up $0.55, and has reached a high of $3.94 today.
The main reason we started the Weekly Wrap is so that we could still teach investors options but also in a safer way. Imax and Dendreon have options that trade but this current recommendation doesn’t.
In the future, shares could if they maintain a level above $5. However, we aren’t worried about selling options against this stock to lower our cost basis because it is a company we want to hold on to for a few years. Regardless of market conditions, this will be an exciting stock to own and we cannot tell you enough how much we believe they have a good story to tell.
Our promotion ended Sunday night for the 6-month Weekly Wrap but we are still getting a ton of emails asking if the offer is still good. Due to demand, we have decided to extend the coupon off for another 24 hours and we said it would be our last deal before our December yearly specials.
The coupon code to use to get the Weekly Wrap 6-month Special Price for $299:
Please copy and paste the code and pick the correct membership on our subscription page to get the deal. We will pull the plug on the offer on Tuesday at midnight. The cost of the newsletter is under $50 a month and is over a 50% savings. This one recommendation will easily pay for the cost of the newsletter.
Once you sign-up, please go to the Weekly Wrap Premium section to get our latest gem.
We have more to talk about in or Members Area so we have to roll but we do hope you hit us up on this offer.
As we head to press, the Dow is down 86 points to 13,121 while the S&P 500 is lower by 7 points to 1,398. The Nasdaq is showing a decline of 15 points to 3,005 but has dipped below 3K. Subscribers, check the Members Area for the updates.